news
Prevenar 13® Indication extended in Japan
23 June 2014 | By Pfizer
Adults 65 or older can now be immunized with the same Pneumococcal Conjugate Vaccine used in children...
List view / Grid view
Pfizer
news
Pfizer and Cellectis enter into global strategic cancer immunotherapy collaboration
19 June 2014 | By Pfizer
Pfizer Inc. and Cellectis announced that they have entered into a global strategic collaboration to develop Chimeric Antigen Receptor T-cell (CAR-T) immunotherapies in the field of oncology directed at select targets...
news
Pfizer opens new state-of-the-art Research and Development Site in Cambridge, Massachusetts
16 June 2014 | By Pfizer
Pfizer Inc. announced the opening of a new 280,000 square-foot Research and Development hub in Cambridge, Mass...
news
Pfizer announces over 10 abstracts for XELJANZ® (Tofacitinib Citrate) in rheumatoid arthritis to be presented at the European League Against Rheumatism Annual Meeting
11 June 2014 | By Pfizer
Additional data further characterizes the safety profile of XELJANZ...
news
Dr. Morris J. Birnbaum joins Pfizer as Chief Scientific Officer, Cardiovascular and Metabolic Disease Research
30 May 2014 | By Pfizer
Pfizer Inc. announced that Morris J. Birnbaum, M.D., Ph.D., has joined the company as Chief Scientific Officer for Cardiovascular and Metabolic Disease Research...
news
Pfizer brings frequent heartburn relief over-the-counter with new Nexium® 24HR
28 May 2014 | By Pfizer
The nation’s most prescribed acid blocker brand is now available without a prescription at retailers nationwide...
news
AstraZeneca Board rejects Pfizer’s final proposal
20 May 2014 | By AstraZeneca
The Board of AstraZeneca PLC notes the announcement by Pfizer Inc. of its final proposal, comprising £24.76 in cash (45%) and 1.747 Pfizer shares (55%) per AstraZeneca share, representing a value of £55.00 per AstraZeneca share (based on the closing price of Pfizer shares on 16 May 2014...
news
American College of Physicians, CECity, and Pfizer collaborate to increase adult immunization rates
16 May 2014 | By Pfizer
Public health initiative aims to increase unacceptably low adult vaccination rates...
news
Statement regarding Pfizer announcement
13 May 2014 | By Astrazeneca
The Board of AstraZeneca PLC notes the announcement made by Pfizer Inc. earlier...
news
Pfizer’s possible offer for AstraZeneca plc represents compelling shareholder value
13 May 2014 | By Pfizer
Pfizer is publishing a presentation to the shareholders of AstraZeneca on the merits of a combination of the two companies...
news
Pfizer confirms prior discussions with AstraZeneca regarding a possible combination and its continuing interest in a possible merger transaction
28 April 2014 | By Pfizer
This is an announcement of a possible offer falling under Rule 2.4 of the City Code on Takeovers and Mergers (the “Code”)...
news
Pfizer announces positive top-line results from two Phase 3 trials of Tofacitinib in adults with moderate-to-severe chronic plaque psoriasis
23 April 2014 | By Pfizer
Pfizer Inc. announced top-line results from two pivotal Phase 3 trials from the Oral treatment Psoriasis Trials (OPT) Program, OPT Pivotal #1 (A3921078) and OPT Pivotal #2 (A3921079)...
news
Pfizer’s novel CDK 4/6 inhibitor palbociclib plus letrozole significantly prolonged progression-free survival in patients with advanced breast cancer
7 April 2014 | By Pfizer
Final Phase 2 PALOMA-1 data to be presented for potential first-in-class palbociclib...
news
In a subanalysis, the benefits of eliquis® (apixaban) vs. Warfarin in reducing the risk of stroke in patients with nonvalvular atrial fibrillation were consistent, regardless of blood pressure control
27 March 2014 | By Bristol-Myers Squibb
Blood pressure control key factor in stroke risk...
news
Pfizer achieves primary endpoint with Phase 3b top-line results of GENOTROPIN® in very young children born small for gestational age
26 March 2014 | By Pfizer
Pfizer Inc. announced the top-line results from a Phase 3B study evaluating the 24-month efficacy of GENOTROPIN®...
